|
Glioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, these data demonstrate that suppression of CCND1 by miR-519d-3p might be a therapeutic target for glioma.<b>Abbreviations</b> miR-519d-3p: microRNA-519d-3p; CCND1: Cyclin D1; ATCC: American Type Culture Collection; MTT: 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide; PI: propidium iodide; WT: wild type; MUT: mutant type; SD: standard deviation.
|
31661371 |
2020 |
|
Methylmalonyl-Coenzyme A mutase deficiency
|
0.010 |
Biomarker
|
disease |
BEFREE |
Isolated methylmalonic aciduria (MMAuria) is primarily caused by deficiency of methylmalonyl-CoA mutase (MMUT or MUT).
|
31770620 |
2020 |
|
Diabetes Mellitus
|
0.010 |
Biomarker
|
group |
BEFREE |
In conclusion, our results demonstrated that inhibition of miR-145-5p might be a neuroprotective target for diabetes mellitus-related DR. <b>Abbreviations:</b> DR: diabetic retinopathy; RGCs: retinal ganglion cells; miR-145-5p: microRNA-145-5p; TNF-α: tumor necrosis factor-α; IL-6: interleukin-6; FGF: fibroblast growth factor; ATCC: American Type Culture Collection; WT: wild type; MUT: mutant type.
|
31272285 |
2019 |
|
Diphtheria
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
DTaP5-HB-IPV-Hib is a fully liquid, hexavalent vaccine containing a 5-antigen pertussis component, approved since 2016 in Europe [Vaxelis; DTaP5-HB-IPV-Hib vaccine: Diphtheria, tetanus, pertussis (5 acellular components: pertussis toxoid [PT], filamentous haemagglutinin [FHA], pertactin (PRN), and fimbriae Types 2 and 3 [FIM]), hepatitis B (recombinant DNA: rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type b conjugate vaccine (adsorbed); MCM Vaccine B.V., The Netherlands] for primary and booster vaccination in infants and toddlers against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases caused by Haemophilus influenzae type b.
|
30882742 |
2019 |
|
Influenza
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
DTaP5-HB-IPV-Hib is a fully liquid, hexavalent vaccine containing a 5-antigen pertussis component, approved since 2016 in Europe [Vaxelis; DTaP5-HB-IPV-Hib vaccine: Diphtheria, tetanus, pertussis (5 acellular components: pertussis toxoid [PT], filamentous haemagglutinin [FHA], pertactin (PRN), and fimbriae Types 2 and 3 [FIM]), hepatitis B (recombinant DNA: rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type b conjugate vaccine (adsorbed); MCM Vaccine B.V., The Netherlands] for primary and booster vaccination in infants and toddlers against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases caused by Haemophilus influenzae type b.
|
30882742 |
2019 |
|
Poliomyelitis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
DTaP5-HB-IPV-Hib is a fully liquid, hexavalent vaccine containing a 5-antigen pertussis component, approved since 2016 in Europe [Vaxelis; DTaP5-HB-IPV-Hib vaccine: Diphtheria, tetanus, pertussis (5 acellular components: pertussis toxoid [PT], filamentous haemagglutinin [FHA], pertactin (PRN), and fimbriae Types 2 and 3 [FIM]), hepatitis B (recombinant DNA: rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type b conjugate vaccine (adsorbed); MCM Vaccine B.V., The Netherlands] for primary and booster vaccination in infants and toddlers against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases caused by Haemophilus influenzae type b.
|
30882742 |
2019 |
|
Tumor Progression
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Our findings revealed that MCM3 promoted radioresistance through activating NF-κB pathway, strengthening the role of MCM subunits in the tumor progression and providing a new target for HCC therapy.
|
31208444 |
2019 |
|
Propionic acidemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Deficiency of propionyl-CoA carboxylase causes propionic acidemia and deficiencies of methylmalonyl-CoA mutase or its cofactor adenosylcobalamin cause methylmalonic acidemia.
|
31451751 |
2019 |
|
Laryngeal Squamous Cell Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Minichromosome maintenance (MCM) protein 4 overexpression is a potential prognostic marker for laryngeal squamous cell carcinoma.
|
29135113 |
2019 |
|
Secondary malignant neoplasm of liver
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Patients with resected CRLM treated at MSKCC with and without adjuvant HAI who had available KRAS status (wild-type, WT; mutated, MUT) were reviewed from a prospectively maintained institutional database.
|
30817353 |
2019 |
|
Multiple Chronic Conditions
|
0.010 |
Biomarker
|
disease |
BEFREE |
The second is a deterministic multi-compartment model (MuSe-MCM) that considers numerous genotypes of the population and where mutations are treated as a transfer of biomass between neighboring genotypes (i.e., a diffusion of characteristics in trait space).
|
30796940 |
2019 |
|
Bowen's Disease
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
To analyze MCM protein expression patterns in actinic keratosis (AK), Bowen disease (BD), and cutaneous squamous cell carcinoma (SCC), we performed immunohistochemical staining of MCM2, -5, and -7 on tissue microarray blocks from 91 AK, 50 BD, and 174 SCC samples.
|
27299186 |
2018 |
|
Cervix Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Risk stratification of cervical disease using detection of human papillomavirus (HPV) E4 protein and cellular MCM protein in clinical liquid based cytology samples.
|
30218891 |
2018 |
|
Conversion disorder
|
0.010 |
Biomarker
|
group |
BEFREE |
The H6P2W18O62/MCM-41-SUP was first synthesized using supercritical impregnation as highly efficient catalyst during glycerol conversion reaction.
|
29442915 |
2018 |
|
Actinic keratosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
To analyze MCM protein expression patterns in actinic keratosis (AK), Bowen disease (BD), and cutaneous squamous cell carcinoma (SCC), we performed immunohistochemical staining of MCM2, -5, and -7 on tissue microarray blocks from 91 AK, 50 BD, and 174 SCC samples.
|
27299186 |
2018 |
|
Neuroblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Currently, a consistent reduction of the MUT protein expression was obtained in the neuroblastoma cell line (SH-SY5Y) by using small-interfering RNA (siRNA) directed against an MUT transcript (MUT siRNA).
|
30428564 |
2018 |
|
Pancytopenia
|
0.010 |
Biomarker
|
disease |
BEFREE |
We report three patients with isolated MUT related MMA who presented with severe refractory pancytopenia during acute illness.
|
29330964 |
2018 |
|
Malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
Moreover, MCMs and PHGDH can be poor prognostic factors for lung cancer.
|
29888431 |
2018 |
|
Squamous cell carcinoma of skin
|
0.010 |
Biomarker
|
disease |
BEFREE |
The diffuse distribution and 50% cut-off value of positive cells revealed statistically significant associations of all MCM proteins with SCC thicker than 6 mm.
|
27299186 |
2018 |
|
Carcinoma of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
Moreover, MCMs and PHGDH can be poor prognostic factors for lung cancer.
|
29888431 |
2018 |
|
Central neuroblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Currently, a consistent reduction of the MUT protein expression was obtained in the neuroblastoma cell line (SH-SY5Y) by using small-interfering RNA (siRNA) directed against an MUT transcript (MUT siRNA).
|
30428564 |
2018 |
|
Alloimmunisation
|
0.010 |
Biomarker
|
disease |
BEFREE |
Cumulative alloimmunization incidence for MUT increased from 0.12% (95% confidence interval [CI], 0.03-0.21) to 0.63% (95% CI, 0.25-1.01), while for Mur it increased from 0.04% (95% CI, 0-0.09) to 0.42% (95% CI, 0.05-0.79) when a patient was transfused 2 RBC units as compared to 12.
|
29441590 |
2018 |
|
Primary malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
Moreover, MCMs and PHGDH can be poor prognostic factors for lung cancer.
|
29888431 |
2018 |
|
Perianal Squamous Intraepithelial Neoplasia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
To analyze MCM protein expression patterns in actinic keratosis (AK), Bowen disease (BD), and cutaneous squamous cell carcinoma (SCC), we performed immunohistochemical staining of MCM2, -5, and -7 on tissue microarray blocks from 91 AK, 50 BD, and 174 SCC samples.
|
27299186 |
2018 |
|
Pancreatic Ductal Adenocarcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The aim of the current study was to investigate the potential prognostic value of minichromosome maintenance (MCM) genes in patients with early-stage pancreatic ductal adenocarcinoma (PDAC) after pancreaticoduodenectomy by using the RNA-sequencing dataset from The Cancer Genome Atlas (TCGA).
|
30233242 |
2018 |